Novel spiro compound
AssigneeMitsubishi Tanabe Pharma Corporation
InventorsNorimitsu HAYASHI, Masaya IKUBO, Akira NAKAO, Shingo OGATA, Minami NAGAOKA, Kenji FUKUNAGA, Rentarou KANNO, Takahiro YAMADA
Life of this patent
Estimating the term…
Loading patent…
AssigneeMitsubishi Tanabe Pharma Corporation
InventorsNorimitsu HAYASHI, Masaya IKUBO, Akira NAKAO, Shingo OGATA, Minami NAGAOKA, Kenji FUKUNAGA, Rentarou KANNO, Takahiro YAMADA
Estimating the term…
The present invention provides a novel spiro compound or a pharmacologically acceptable salt thereof that has a TRH-DE inhibitory activity and is useful for preventing or treating various diseases associated with TRH and/or symptoms associated therewith, a method for producing the same, a use thereof, and a pharmaceutical composition containing the compound or the pharmacologically acceptable salt thereof as an active ingredient. There is provided a compound represented by the following Formula [I]: wherein, a ring A represents an aryl group which may be substituted, a heteroaryl group which may be substituted, or an aliphatic heterocyclyl group which may be substituted, and R1 and R2 represent, independently, an alkyl group which may be substituted, a cycloalkyl group which may be substituted, an alkenyl group which may be substituted, a cycloalkenyl group which may be substituted, an alkynyl group which may be substituted, an aryl group which may be substituted, a heteroaryl group which may be substituted, an aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring, an amino group which may be substituted, an alkoxy group which may be substituted, or an alkylthio group which may be substituted, or a group in which R1 and R2 together form a ring, or a pharmacologically acceptable salt thereof.
A compound represented by the following Formula [I] or a pharmacologically acceptable salt thereof:
A compound selected from the group consisting of:
35-45. (canceled)
(3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-8-(trifluoromethyl)-2,3-dihydropyrido[3,4-f][1,4]oxazepin-5-one, or a pharmacologically acceptable salt thereof.
(6R)-2-cyclopropyl-5-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-7,8-dihydro-6H-pyrazolo[1,5-a][1,4]diazepin-4-one, or a pharmacologically acceptable salt thereof.
(3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3,8-dimethyl-2,3-dihydropyrido[3,4-f][1,4]oxazepin-5-one, or a pharmacologically acceptable salt thereof.
(6R)-2-cyclopropyl-7-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-5,6-dihydrothiazolo[5,4-f][1,4]oxazepin-8-one, or a pharmacologically acceptable salt thereof.
Dependencies are inferred from the claim text.